Biotech
Biotechnology companies developing novel therapeutics for lupus and autoimmune conditions.
What We Fund
The Fund has a broad mandate to invest in any technology that has the potential to improve the standard of care and improve quality of life for patients living with lupus, across all stages of development (preclinical, Ph1/2/3, and commercial), and private financing rounds (NewCo, Seed, Series A, B, C, etc.).
Pharma
Pharmaceutical companies advancing potential therapies through clinical development and commercialization.
Diagnostics
Companies developing diagnostic tools and biomarkers to improve lupus detection and monitoring.
MedTech
Medical technology companies creating devices to support lupus patient care.
Digital Health
Companies leveraging digital platforms, data, and software to improve lupus outcomes.
Others
Other innovative technologies with the potential to improve the standard of care for lupus patients.
May 19, 2026